Primary evaluation of antioxidant status oligomineral patient with type 2 diabetes Algeria: Special interest manganese and chromium;Évaluation primaire du statut antioxydant oligominéral chez le patient diabétique de type 2 algérien: intérêt particulier du manganèse et du chrome

Annales de Biologie Clinique

Volumn 70, Issue 6, 2012, Pages 669-677

  Harani, Hassiba ^a,c   Otmane, Amel ^b   Makrelouf, Mohamed ^b   Ouadahi, Nacer ^b   Abdi, Arezki ^b   Berrah, Abdelkrim ^b   Zenati, Akila ^b   Alamir, Barkahoum ^b   Koceir, Elhadj Ahmed ^a  

^a UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^b University of Algiers   (Algeria)

^c Ecole Normale Superieure de Kouba   (Algeria)

Author keywords

Chromium; Insulin resistance; Manganese; Oxidative stress; Trace elements; Type 2 diabetes

Indexed keywords

ANTIOXIDANT; CHROMIUM; GLYCOSYLATED HEMOGLOBIN; MANGANESE; SELENIUM; TRACE ELEMENT; ZINC;

ADULT; ALGERIA; ALGORITHM; ARTICLE; BLOOD; BODY MASS; COHORT ANALYSIS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; REFERENCE VALUE; RISK FACTOR;

ADULT; ALGERIA; ALGORITHMS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY MASS INDEX; CHROMIUM; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MANGANESE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; REFERENCE VALUES; RISK FACTORS; SELENIUM; TRACE ELEMENTS; ZINC;

EID: 84870863334     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2012.0763     Document Type: Article

References (43)

1. Berger MM. Éléments traces. In: Leverve X, Cosnes J, Erny P, Hasselmann M, eds. Traité de nutrition artificielle de l'adulte. 2e édition. Paris: Springer-Verlag, 2001: 127-40.
2. Wiernsperger N, Rapin JR.Trace elements in glucometabolic disorders: an update. Diabetol Metab Syndr 2010; 2: 70.
3. Viktorinova A, Toserova E, Krizko M, Durackova Z. Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus. Metabolism 2009 ; 58: 1477-82.
4. Kazi TG, Afridi HI, Kazi N, Jamali MK, Arain MB, Jalbani N, et al. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus Patients. Biol Trace Elem Res 2008; 122: 1- 18.
5. Fitsanakis VA, Zhang N, Garcia S, Aschner M. Manganese (Mn) and iron (Fe): interdependency of transport and regulation. Neurotox Res 2010 ; 18: 124-31.
6. Food and nutrition board of the institute of medicine. Dietary reference intakes for vitamin A, vitamin K, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc.Washington DC: National Academy Press, 2001: www.nutrisci.wisc.edu.
7. Alves G, Thiebot J, Tracqui A, Delangre T, Guedon C, Lerebours E. Neurologic disorders due to brain manganese deposition in a jaundiced patient receiving long-term parenteral nutrition. J Parenter Enteral Nutr 1997 ; 21: 41-5.
8. American diabetes association. Standards of medical care in diabetes 2006. Diabetes Care 2006 ; 29 (Suppl. 1): S4-42.
9. Balkau B, Valensi P, Eschwège E, Slama G. A review of the metabolic syndrome. Diabetes Metab 2007 ; 33: 405-13.
10. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin résistance and B cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985 ; 28: 412-9.
11. Arnaud J, Bellanger J, Bienvenu F, Chappuis P, Favier A. Recommanded method for assaying serum zinc with flame atomic absorption. Ann Biol Clin 1986 ; 44: 77-87.
12. Favier A. Le stress oxydant: intérêt de sa mise en évidence en biologie médicale et problèmes posés par le choix d'un marqueur. Ann Biol Clin 1997 ; 55: 9-16.
13. Richard MJ, Belleville F, Chalas J, Ceballos-Picot I, Vitoux D, Boyer MJ, et al. Les glutathion peroxydases: intérêt de leur dosage en biologie clinique. Ann Biol Clin 1997 ; 55: 195-208.
14. Koracevic D, Koracevic G, Djordjevic VG, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001 ; 54: 356-61.
15. Fernandez EB. Glucolipotoxicity, resistance to the action of insulin and type 2 diabetes mellitus. An R Acad Nac Med 2007 ; 124: 547-56.
16. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro-and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 2011 ; 7: 313-24.
17. Ferry M. Fonctions des oligoéléments. In: Leverve X, Cosnes J, Erny P, Hasselmann M, eds. Traité de nutrition artificielle de l'adulte. 2e édition. Paris: Springer-Verlag, 2001: 36-41.
18. Klimis-Zacas D, Kalea A. Manganese. Modulator of vascular function, structure, and metabolism. Cell Biol Toxicol 2008; 24: S1-S130.
19. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev 2009 ; 5: 120-44.
20. Malecki EA, Greger JL. Manganese protects against heart mitochondrial lipid peroxidation in rats fed high levels of polyunsaturated fatty acids. J Nutrition 1996 ; 126: 27-33.
21. Ekmekcioglu C, Prohaska C, Pomazal K, Steffan I, Schernthaner G, Marktl X. Concentrations of seven trace elements in different hematological matrices in patients with type 2 diabetes as compared to healthy controls. Biol Trace Elem Res 2001 ; 79: 205-19.
22. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes & Metabolism 2003 ; 29: 6S88-6S94.
23. Vincent JB. Chromium: celebrating 50 years as an essential element? Dalton Trans 2010 ; 39: 3787-94.
24. Iskra RI, Ianovych VG. Biochemical mechanisms of chromium action in the human and animal organism. Ukr Biokhim Zh 2011 ; 83: 5-12.
25. Zhao P, Wang J, Ma H, Xiao Y, He L, Tong C. A newly synthetic chromium complex-chromium [D-phenylalanine] 3 activates AMPactivated protein kinase and stimulates glucose transport. Biochem Pharmacol 2009 ; 77: 1002-10.
26. Sreejayan N, Marone PA, Lau FC, Yasmin T, Bagchi M, Bagchi D. Safety and toxicological evaluation of a novel chromium [III] dinicocysteinate complex. Toxicol Mech Methods 2010 ; 20: 321-33.
27. Fuhr JP Jr, He H, Goldfarb N, Nash DB. Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. Dis Manag 2005 ; 8: 265-75.
28. Lai MH. Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and E supplementation for type 2 diabetes mellitus. J Clin Biochem Nutr 2008 ; 43: 191-8.
29. Qiao W, Peng Z, Wang Z, Wei J, Zhou A. Chromium improves glucose uptake and metabolism through upregulating the mRNA levels of IR, GLUT4, GS, and UCP3 in skeletal muscle cells. Biol Trace Elem Res 2009 ; 131: 133-42.
30. Vladeva SV, Terzieva DD, Arabadjiiska DT. Effect of chromium on the insulin resistance in patients with type II diabetes mellitus. Folia Med (Plovdiv) 2005 ; 47: 59-62.
31. Krol E, Krejpcio Z, Byks H, Bogdanski P, Pupek-Musialik D. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol Trace Elem Res 2011 ; 143: 726-37.
32. Wang YQ,Yao MH. Effects of chromium picolinate on glucose uptake in insulin-resistant 3T3-L1 adipocytes involve activation of p38 MAPK. J Nutr Biochem 2009 ; 20: 982-91.
33. Anton SD, Morrison CD, Cefalu WT, Martin CK, Coulon S, Geiselman P, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther 2008 ; 10: 405-12.
34. Wang YQ, Dong Y, Yao MH. Chromium picolinate inhibits resistin secretion in insulin-resistant 3T3-L1 adipocytes via activation of ampactivated protein kinase. Clin Exp Pharmacol Physiol 2009 ; 36: 843-9.
35. Jain SK, Rains JL, Croad JL. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med 2007; 43: 1124- 31.
36. Vinson JA, Mandarano MA, Shuta DL, Bagchi M, Bagchi D. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model. Mol Cell Biochem 2002 ; 240: 99-103.
37. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 2007 ; 147: 217-23.
38. Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta 2009 ; 1790: 1478-85.
39. Kornhauser C, Garcia-Ramirez JR, Wrobel K, Pérez-Luque EL, Garay-Sevilla ME, Wrobel K. serum selenium and glutathion peroxidase concentrations in type 2 diabetes mellitus patients. Prim Care Diabetes 2008 ; 2: 81-5.
40. Rayman MP. Selenium and human health. Lancet 2012; 379: 1256- 68.
41. Ozkaya M, Sahin M, Cakal E, Gisi K, Bilge F, Kilinc M. Selenium levels in first-degree relatives of diabetic patients. Biol Trace Elem Res 2009 ; 128: 144-51.
42. Zheng HT, Zhou LN, Huang CJ, Hua X, Jian R, Su BH. Selenium inhibits high glucose- and high insulin-induced adhesion molecule expression in vascular endothelial cells. Arch Med Res 2008 ; 39: 373-9.
43. Xun P, Liu K, Morris JS, Daviglus ML, He K. Longitudinal association between toenail selenium levels and measures of subclinical atherosclerosis: the Cardia trace element study. Atherosclerosis 2010 ; 210: 662-7.